Denali Therapeutics (DNLI) Current Assets (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Current Assets data on file, last reported at $1.0 billion in Q1 2026.

• On a quarterly basis, Current Assets rose 16.4% year-over-year to $1.0 billion in Q1 2026; TTM through Mar 2026 was $1.0 billion, a 16.4% increase from a year earlier, with the FY2025 full-year figure at $900.7 million, up 4.19% from the prior year.
• Current Assets for Q1 2026 stood at $1.0 billion, up from $900.7 million in the prior quarter.
• Over the last five years, Current Assets for DNLI reached as high as $1.4 billion in Q4 2022 and fell as low as $864.4 million in Q4 2024.
• Historically, Current Assets has averaged $1.0 billion across 5 years, with a median of $988.4 million in 2022.
• On a YoY basis, Current Assets climbed as much as 52.95% in 2022 and fell as far as 30.96% in 2022.
• Year by year, Current Assets stood at $1.4 billion in 2022, then fell by 22.46% to $1.1 billion in 2023, then dropped by 18.77% to $864.4 million in 2024, then rose by 4.19% to $900.7 million in 2025, then rose by 13.56% to $1.0 billion in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $1.0 billion in Q1 2026, $900.7 million in Q4 2025, and $882.6 million in Q3 2025.